Gujarat Themis Biosyn Limited reported a revenue of ₹16,582.28 lakh for the financial year 2026, with an EBITDA margin of 45.55%. The company disclosed its strategic initiatives, including the acquisition of MicroBiopharm Japan and a select product portfolio from Sanofi, to enhance its fermentation capabilities and diversify its product range. These moves are aimed at transforming the company into a diversified pharmaceutical platform with a global presence.

The company’s annual fermentation capacity doubled to 990 KL in FY26 from 450 KL in FY25, supporting its forward integration into Active Pharmaceutical Ingredients (API) production. Gujarat Themis Biosyn specializes in fermentation-based intermediates and APIs, focusing on anti-tuberculosis and anti-infective products. The new R&D lab established in Valsad, Gujarat, is GMP-approved and focuses on developing new intermediate molecules.

Financial performance for FY26 showed a Profit After Tax (PAT) of ₹4,668.15 lakh, a decrease from ₹5,916.32 lakh in FY24. The company’s Return on Capital Employed (ROCE) stood at 14.50% in FY26, down from 39.40% in FY24, while Return on Equity (ROE) was 16.20% compared to 29.40% in FY24. The finance costs increased significantly to ₹294.89 lakh in FY26 from ₹22.92 lakh in FY24.

The acquisition of MicroBiopharm Japan, subject to regulatory approvals, is expected to enhance GTBL's fermentation and precision biotech capabilities. The Japanese entity reported a revenue of JPY 9.5 Bn (INR 561.82 Crs) in FY26 and operates three GMP-compliant plants with FDA and PMDA approval track records. This acquisition will provide access to advanced technologies such as plasmid DNA, ADC conjugation, and enzyme engineering.

In a separate transaction, Gujarat Themis Biosyn entered into an agreement with Sanofi to acquire a select product portfolio of anti-tuberculosis and anti-infective brands. The portfolio generated €62 million in net sales in CY25 and includes 13 brands marketed across 59 countries, primarily in the Middle East & Africa and Europe. The deal, valued at €158 million, is structured as an asset deal including marketing authorizations, regulatory documentation, and inventory, without the transfer of manufacturing facilities or employees.

Financial Highlights (INR Lakhs)

Capacity Expansion

Gujarat Themis Biosyn Limited has initiated arbitration proceedings against Optimus Drugs Private Limited to recover damages following the termination of a supply agreement. The company claims the termination occurred contrary to the agreed terms and has approached a Learned Sole Arbitrator to resolve the dispute. The total claim amounts to ₹113.8 crore, covering break fees, interest, and financial losses incurred due to the breach of contract.

Details of the dispute

Optimus Drugs allegedly breached the mandatory "Take-or-Pay" minimum purchase obligations outlined in the agreement. Consequently, Gujarat Themis Biosyn is seeking specific recoveries from the respondent. The company asserts that the termination was unjustified and has resulted in significant financial impact, necessitating legal intervention to enforce the terms of the original contract.

Breakdown of claims

The arbitration filing details several components of the financial claim being pursued by Gujarat Themis Biosyn. The company is seeking restitution for specific breaches and the resultant monetary damages.

Financial implications and regulatory filing

Gujarat Themis Biosyn stated that since it has initiated the arbitration proceeding claiming recovery and damages, it does not anticipate any adverse financial implications arising from penalties. The disclosure was made to the BSE Limited and National Stock Exchange of India Limited on June 26, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted by Vineet Gawankar, Company Secretary & Compliance Officer.